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Anaphylaxis and Biphasic Phase in
Thailand: 4-year Observation
Ratchaya Lertnawapan1 and Wirach Maek-a-nantawat2,3
ABSTRACT
Background: Anaphylaxis, a severe systemic allergic reaction, can be fatal. However, its prevalence has
been underestimated especially in biphasic phase, due to a lack of case awareness. This study aimed to deter-
mine the rate of anaphylaxis, describe clinical manifestations and management, and identify the causative
agents and risk factors of biphasic anaphylactic reaction.
Methods: An observational study was conducted at the Emergency Department of Thammasat University
Hospital, Thailand, during the period 2004-2008.
Results: Of total 208 cases of anaphylaxis identified, the median age was 20.67 years; 52.9% were male. The
anaphylaxis rate was 49 per 100,000 patient-years. No fatal case was found; 58.7% had a history of atopy, and
38.5% had experienced a previous allergic reaction, of whom 8.8% had had a previous anaphylactic reaction.
The causative allergens were identified in 82.2% of cases; food allergy was most common. Urticaria was the
most common presentation (87%). Among 6.3% of the patients who developed biphasic reaction, a significantly
longer time from onset of symptoms to administration of epinephrine was detected, with a median of 240 min-
utes for those with biphasic anaphylaxis, versus 70 minutes for those without (p = 0.002). The median times
from onset to hospital arrival and the arrival to administration of epinephrine were also significantly longer in the
biphasic group than the non-biphasic patients (p = 0.002 and p = 0.001, respectively). In multivariable regres-
sion models, the time intervals from onset and hospital arrival to administration of epinephrine continued to pre-
dict biphasic phase occurrence (p < 0.01).
Conclusions: Anaphylaxis predominantly occurs among children and young adults. Delayed administration of
epinephrine was associated with the occurrence of biphasic anaphylaxis.
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INTRODUCTION
Anaphylaxis, an acute, serious, potentially fatal sys-
temic allergic reaction, can manifest in a variety of
presentations, onsets, appearances, and severities. In
the US, 1-3% of the population is estimated to be at
risk of anaphylaxis.1 The incidence of anaphylaxis in
the UK was 6.7 per 100,000 person-years in 2001, and
increased by 19% to 7.9 per 100,000 in 2005.2 This
trend implies the emerging incidence and impact of
this medical problem. In Thailand, the incidence of
anaphylaxis was 21 per 100,000 person-years, with a
fatality rate of 0.65% of cases.3 The annual occurrence
of anaphylaxis increased from 9.16 per 100,000 admit-
ted persons in 1999, to 55.45 per 100,000 admitted
persons in 2004, and the case fatality rate was 0.19
per 100,000 admitted persons.4 Epidemiologic infor-
mation about anaphylaxis in Thailand is likely to be
underestimated.
Many contributing factors masking the actual inci-
dence of anaphylaxis include unawareness;5 non-
identification,5,6 especially in some circumstances
such as the perioperative period; emergencies, and
life-saving or unconditional management and death
with unidentified cause (SUDS); and missed diagno-
sis6 of a case presenting mild symptoms. Using the
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diagnostic criteria for anaphylaxis outlined by the
2006 Symposium on the Definition and Management
of Anaphylaxis, sponsored by the National Institute of
Allergy and Infectious DiseaseFood Allergy and
Anaphylaxis Network,7 few studies have been pub-
lished demonstrating the incidence and clinical char-
acteristics of anaphylaxis. The objectives of this study
were to describe the clinical manifestations and man-
agement of anaphylaxis according to the criteria, and
to identify the causative agents and risk factors of
biphasic anaphylaxis.
METHODS
A cohort study was conducted in Thammasat Univer-
sity Hospital, Prathumthani Province, Thailand, and
was approved by the Ethics Committee of the Faculty
of Medicine, Thammasat University (Rangsit Cam-
pus). All suspected cases seen at the emergency de-
partment of the hospital from 1 July 2004 to 30 Sep-
tember 2008 were enrolled into the study. The cases
of anaphylaxis were defined by a physician in charge
and had to satisfy one of the following diagnostic cri-
teria7: 1) acute onset of an illness with involvement of
the skin, mucosal tissues, or both, in combination
with at least one of the following: respiratory compro-
mise or reduced blood pressure or symptoms associ-
ated with terminal organ dysfunction, 2) two or more
of the following combinations, which occur rapidly af-
ter exposure to a likely allergen: involvement of the
skin-mucosal tissues, respiratory compromise, re-
duced blood pressure, or persistent gastrointestinal
symptoms, and 3) reduced blood pressure after expo-
sure to a known allergen for that patient. In addition,
all cases sorted by the discharge diagnostic codes us-
ing the 9th and 10th version International Classifica-
tion of Diseases (ICD) and defined as the following
terms: anaphylaxis, angioedema, urticaria, shock,
syncope, food allergy, drug allergy, insect allergy, in-
sect sting, and allergic reaction, were reviewed by the
allergist of the Department of Medicine, Thammasat
University, for retrospective recruitment into this
study.
Data collection included demographic data, history
of atopic disease and allergic disease, food allergy
and drug allergy, previous anaphylaxis, family history
of atopy, underlying disease and medication, time
from allergen contact to onset of symptoms, type of
culprit allergen, and clinical manifestations. In all pa-
tients, skin reactivity was tested on the volar surface
of the forearm by the same trained and experienced
person. The results were read at 15 min. A positive
result yields a wheal at least 3 mm in diameter larger
than the negative control (glycerinated phenol-
saline). The studied allergens (Alk-Abello; Lincoln Di-
agnostics, Dallas, TX, USA), included 13 food aller-
gens: egg white, egg yolk, cow’s milk, beef, pork,
mixed fish (Flounder, Cod, Halibut), wheat, mixed
shellfish (crab, shrimp, lobster, oyster), peanut, soy-
bean, cocoa bean, green pea and yeast; and 12 aero-
allergens composed of molds (Aspergillus, Penicillum,
Cladosporium), pollens (paragrass, bermuda grass,
careless weed), house dust, mites (Dermatophagoides
pteronyssinus, Dermatophagoides farinae), cat hair,
dog epithelium and cockroaches.
Sample size estimation using Epi Info 6 was 138,
based on acceptable biphasic-phase occurrence range
of 5-15%, with 95% confidence interval. All data was
entered and analyzed using the statistical software
SPSS version 17. Qualitative data were expressed as
percent. Chi-square testing was performed for uni-
variate analysis of the relationship between dichoto-
mous clinical variables and outcome variables of
biphasic reactions. The unpaired t-test was used for
univariate analysis of continuous clinical predictor
variables and outcome variables of biphasic reactions.
The Mann-Whitney U test was used to analyze corre-
lations in nonparametric data. Logistic regression
was used for multivariate analysis to determine the
independent association of factors related to occur-
rence of biphasic phase of anaphylaxis. A p-value
< 0.05 was considered statistically significant.
RESULTS
A total of 208 cases of anaphylaxis were identified and
fulfilled the diagnostic criteria. We calculated the oc-
currence from the total attendances of all patients
during that period; the rate of anaphylaxis in the
emergency department was 49 per 100,000 patients
per year. No fatal cases were reported.
DEMOGRAPHIC DATA
Demographic data and underlying atopy are pre-
sented in Table 1. There were 110 (52.9%) male cases
and 98 (47.1%) female cases. The median (range) age
of patients was 20.67 (1 month to 70 years). Most pa-
tients were children and young adults. Fifty-eight
point seven percent of patients had a positive atopic
history. Associated atopy was classified into allergic
rhinitis (24.5%), atopic dermatitis (2.9%), asthma
(16.3%), urticaria (4.8%), drug allergy (17.3%), and
food allergy (22.6%). Previous allergic reactions were
reported in 83 (39.9%) patients. Seven cases (3.4%)
had previous anaphylactic reactions. Surprisingly, all
of these had developed anaphylaxis from the same
cause as the previous anaphylactic reaction.
CAUSATIVE ALLERGEN
One hundred seventy-one patients (82.2%) could iden-
tify the culprit (Fig. 1). By medical history, food was
the most common causative allergen. Of the 93 cases
(44.7%) for whom food was the trigger, the most com-
mon was seafood (45.2%), including shrimp (24.7%)
and crab (9.7%), followed by seafood (unspecified or
mixed) (8.6%), and squid (4.3%). Fried-insect-(such as
grasshoppers) induced anaphylaxis was noted in
23.6% of cases. Other causes of food-trigger anaphy-
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Table　1　Baseline characteristics, clinical manifestations and initial treatment of 208 anaphylactic patients
Characteristics
Non-biphasic 
anaphyalxis 
N = 195
Biphasic 
anaphylaxis 
N = 13
P-value
Male (%) 106 (54.4) 4 (30.8) 0.173
Median age, years 22 18.5 0.564
Atopy (%) 118 (60.5) 4 (30.8) 0.069
- Allergic rhinitis (%) 47 (22.6) 4 (30.8) 0.526
- Asthma (%) 31 (15.9) 3 (23.1) 0.771
- Food allergy (%) 45 (23.1) 2 (15.4) 0.764
Drug allergy (%) 36 (18.5) 0 0.13
Previous allergic reactions (%) 78 (40) 5 (38.5) 0.855
Underlying disease (%) 87 (44.6) 5 (38.5) 0.885
Presenting symptoms:
・Urticaria/angioedema (%) 169 (86.7) 12 (92.3) 1.00
・Bronchospasm (%) 100 (51.3) 4 (30.8) 0.252
・Abdominal pain (%) 57 (29.2) 7 (53.8) 0.121
・Hypotension (%) 63 (32.3) 5 (38.5) 0.879
・Shock (%) 56 (28.7) 5 (38.5) 0.665
・Unconsciousness (%) 7 (3.6) 1 (7.7) 0.409
Treatment:
・Intramuscular injection of epinephrine (%) 170 (87.2) 13 (100) 0.467
・Epinephrine use (%) 192 (98.5) 12 (92.3) 0.229
・Injected H1 antagonist (%) 180 (92.3) 11 (84.6) 0.288
・Injected H2 antagonist (%) 114 (58.5) 9 (69.2) 0.636
・Steroid use (%) 169 (86.7) 10 (76.9) 0.398
・Beta-agonist use via nebulizer (%) 59 (30.3) 4 (30.8) 1.00
Time Interval (from onset to treatment) Median (IQR) Median (IQR)
・Time from Contact ― Onset (min.) 30 (17.5-107.5) 120 (10-240) 0.501
・Time from Onset ― Hospital Arrival (min.) 60 (30-120) 180 (105-360) 0.002
・Time from Onset ― Epinephrine (min.) 70 (40-135) 240 (122.5-380) 0.002
・Time from Hospital Arrival ― Epinephrine (min.) 15 (10-15) 25 (16.5-30) 0.001
Fig.　1　Possible causes of anaphylaxis (N = 171).
Percents
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laxis included fish (11 cases), wheat (7 cases), and
cow’s milk (4 cases). Medications and herbs were the
second-most common groups of allergens. 55 cases
(26.4%) of anaphylaxis caused by medications were
classified into drugs (49 cases), herbs (2 cases), vac-
cine (1 case), and immunotherapy (3 cases). The
types and names of the medications causing anaphy-
laxis are grouped in Table 2. Insect stings were also
detected as a cause of anaphylaxis in 16 cases (7.7%).
Exercise-induced anaphylaxis was noted in 4 cases
(1.9%). Other identified causes were chemicals (1
case) and blood product (1 case). However, 37 pa-
tients (17.8%) could not identify their possible trig-
gers.
CLINICAL MANIFESTATIONS AND MANAGE-
MENT
The median time (range) of the latent period, from al-
lergen culprit exposure to first presenting symptom,
was 69.5 (5-4200) minutes. The common signs and
symptoms are also shown in Table 1. Anaphylactic
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Table　2　Drug-induced anaphylaxis (N = 49)
Causative Agent Patient number Percent
NSAIDS 17 34.7
Beta-lactams 12 24.5
Quinolones 4 8.2
Paracetamol 3 6.15
Cephalosporin (ceftriaxone) 2 4.1
Sulfa 2 4.1
Tolperisone 1 2.05
Desferrioxamine 1 2.05
Nicotinamide 1 2.05
Omeprazole injection 1 2.05
Streptokinase 1 2.05
Aminoglycoside 1 2.05
Xylocaine 1 2.05
shock was identified in 29.3% of cases. Dermatologic
symptoms, including urticaria (87%), angioedema
(70.7%), and pruritus (69.7%), were most commonly
detected symptoms among anaphylactic cases. Oral
pruritus and flushing were noted in 19.7 and 26.4% of
cases, respectively. Respiratory symptoms included
dyspnea (50%), wheezing (39.4%), and hoarseness of
voice (3.8%). Abdominal cramps, nausea and diarrhea
were noted commonly, at 30.8, 42.8, and 19.2%, re-
spectively. Syncope and hypotension could be found
in 18.8 and 32.7% of cases, respectively. Neurological
symptoms, including seizure and unconsciousness,
were uncommon. Skin prick tests (SPT) were per-
formed in 46 cases (22.1%), of which 82.6% were SPT-
positive with clinically confirmed for causative aller-
gen. A negative SPT result was found in 8 cases
(17.4%). Specific IgE by RAST test or Immunocap
were performed in only 2 cases (1%), and showed
positive results in both patients. An oral food-
challenge test was performed with one patient, with a
positive result. No exercise-challenge test was per-
formed.
Two hundred and four patients (98.1%) were given
epinephrine. The median time interval from onset of
symptom to first administration of epinephrine was 75
minutes (IQR 40-137.5). The routes of injection were
intramuscular (88%), subcutaneous (9.6%), and intra-
venous (0.5%). Other drugs prescribed included ster-
oids (86.1%), H1-receptor antagonist (91.8%), H2-
antagonist (59.1%), and beta-adrenergic agonist
(30.3%) (Table 1). Only 8 patients (3.8%) received self-
administered epinephrine or auto-injection epineph-
rine (Epipen) at the time of discharge. The mean
length of hospitalization was 1.2 days.
BIPHASIC REACTION
Anaphylaxis resolved acutely for every patient. How-
ever, biphasic reactions were detected in 13 patients
(6.25%), 9 females and 4 males. The time from initial
event to onset of second reaction ranged from 2 to 13
hours, with a mean of 7.84 hours. One case was docu-
mented as protracted anaphylactic reaction. The aller-
gens involved in the biphasic-reaction group were
shrimpseafood (30.8%), fried insect as food (15.4%),
immunotherapy (15.4%), insecticide (7.7%), and un-
known cause (30.8%). Five of 13 patients had a his-
tory of previous allergic reaction caused by the same
culprit allergen. Atopic disease and documented ana-
phylactic shock were detected in 30.8 and 38.5% of
cases, respectively. All biphasic patients had symp-
toms and signs involving organ systems similar to
their presentation in their initial phase.
There was no significant difference in baseline
characteristics between patients with and without
biphasic anaphylaxis. In addition, other clinical pa-
rameters, such as atopic disease, triggers, precipitat-
ing factors (i.e. food, exercise, and medication), clini-
cal manifestations and treatment, were not signifi-
cantly different between the two groups (Table 1).
There was no significant difference in time from in-
itial exposure of the presumptive culprit to onset of
reaction between patients with and without biphasic
anaphylaxis (p = 0.5). Regarding treatment of initial
anaphylaxis, intramuscular epinephrine and steroid
were administered in 92.3 and 76.9% of cases, respec-
tively. Steroid administration was not statistically sig-
nificantly different between biphasic and non-biphasic
patients. The median time interval (minutes) from on-
set to administration of epinephrine was significantly
longer in the biphasic group than the non-biphasic pa-
tients, at 240 (IQR 122.5-380) vs 70 (IQR 40-135) min-
utes, p = 0.002 (Table 1, Fig. 2). Also the median time
interval (minutes) from hospital arrival to administra-
tion of epinephrine was significantly longer in the
biphasic group than the non-biphasic patients, at 25
(IQR 16.5-30) vs 15 (IQR 10-15) minutes, p = 0.001.
Furthermore, the median time interval (minutes)
from onset to hospital arrival was longer in the bipha-
sic group than the non-biphasic group, at 180 (IQR
105-360) vs 60 (IQR 30-120), p = 0.002. However,
there was no statistical difference between the me-
dian time interval from contact to onset of symptoms
(Table1). In multivariable regression models, the
time intervals from reaction onset to hospital arrival
and the onset and arrival to administration of epi-
nephrine continued to predict biphasic phase occur-
rence (p < 0.01).
DISCUSSION
The prevalence of anaphylaxis is increasing, as found
in this study and previous studies.2,8 Age distribution
predominated in child and young adult groups; how-
ever, being elderly might be a risk factor contributing
to anaphylaxis-related death, for which the likelihood
increases with increasing age.9 The lack of fatal cases
in this study may be explained with the young study
population with the mean age of 20.67 years. This
Anaphylaxis and Biphasic Phase
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Fig.　2　Time from onset to administration of epinephrine in patients with and with-
out biphasic phase, p = 0.002 (N = 208).
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study was also conducted in a hospital remote from
surrounding communities, so it is possible that se-
vere cases might not reach the hospital in time. Also,
some anaphylactic events during hospitalization, re-
lated to operations or medical interventions, were not
included in this study. Other recent studies have de-
tected low to rare anaphylaxis-associated death rates,
with mortality at 0.0001%10 and 0.19 per 100,000.4
Over two thirds of the patients had previous atopic
history, which was similar to other studies.11 Surpris-
ingly, the previous allergic and previous anaphylactic
reactions were detected at lower rates than a previ-
ous study.11 This finding might be related to a lack of
recognition in a case of mild reaction.
Like previous studies,1,3,10,12-14 the most commonly
identified allergen was food. This is consistent with
the increasing incidence of food allergy, which is 3-4%
in the general population and 5% in children.12 How-
ever, the kinds of food causing anaphylaxis differ
from country to country; e.g., peanuts in Western de-
veloped countries.15 Peanut allergy is found among
1% of Western populations,16 but scarcely among
Asian populations.17 We found the food most com-
monly inducing anaphylaxis was seafood, which
caused nearly half of all food-related anaphylaxis, and
one-quarter of all cases. These findings are supported
by other studies,8,11 but contrast with a study from Ja-
pan18; this might be explained by the lifestyles in the
developed world or a history of high seafood expo-
sure in an affected area. A history of food anaphylaxis
related to fried insects, which has never been re-
ported from other countries, was also detected. Fried
insects caused anaphylaxis in about one-quarter of
food-related anaphylaxis, which is relatively higher
than has been reported in the USA.19
Medication-associated anaphylaxis is important
among adults and children. Antibiotics and analgesics
are the most common culprits of anaphylaxis. Al-
though immunotherapy-related anaphylaxis is possi-
ble, it rarely occurs; it is safe for selected atopic
cases.20,21 We did not find any case of food-dependent
exercise-induced anaphylaxis, which is a rare and
easily underestimated disease. Among the skin-prick-
test cases, we found the test yielded positive results
among 82.6% of patients. This conclusion should en-
courage physicians to perform skin-prick tests to con-
firm a diagnosis and to improve further management.
This study emphasized the assessment of early de-
tection, management, and short-term outcomes of
anaphylaxis. We found the latent periods from con-
tact with the allergen to onset of symptom were 5
minutes to 70 hours (median 30 minutes, mean
123.94 minutes). The mean duration was double that
of a previous study.11 This could be related to the
study setting and recall bias in a study using a ques-
tionnaire. Regarding the clinical manifestations of
anaphylaxis in our study, the most common presenta-
tion was cutaneous symptoms, especially urticaria,
which is similar to previous studies.22,23 In our institu-
tion, the treatment of anaphylaxis, by giving intra-
muscular epinephrine, following published guideline7
was 87.5%. The overall usage of epinephrine in all
routes of injection (intramuscular, intravenous, and
subcutaneous) was 98.1% of cases. This finding con-
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trasts with other studies showing lower rates of epi-
nephrine use.4,24 The high rate of epinephrine use in
the treatment of anaphylaxis might result from recent
intensive emergency training for medical staff. One
patient was given intravenous epinephrine due to cir-
culatory collapse. However, steroids, H1 and H2 an-
tagonists, and beta-adrenergic agonists, were pre-
scribed in 86, 91.8, 86, and 30.8% of cases, respec-
tively, which is comparable with previous studies.25,26
Biphasic reaction was detected in 6.25% of cases,
which is similar to previous studies.27-29 Its incidence
ranges from 1 to 20% of all episodes.30 The severity
could be less severe, equally severe, or more severe
than the initial reaction, ranging in degree from mild
symptoms to fatal reactions.31 The occurrence of
biphasic reaction might be affected by early manage-
ment and early recognition of cases. Although 30% of
biphasic anaphylactic cases had a history of atopy, it
could not be identified as a risk factor. The latent pe-
riod, from initial phase to biphasic phase in our study,
ranged from 2 to 13 hours. The reaction may even oc-
cur later, up to 72 hours after resolution of the pri-
mary event,30 so that anaphylactic patients should be
observed for at least 24 hours.28,32,33 Although steroid
administration was detected, it seemed that its use
did not prevent biphasic reaction.28,29,34
From our study, the time from onset to the admini-
stration of epinephrine is the predisposing determi-
nant of biphasic reaction, in which there was a signifi-
cantly longer median time from onset to administra-
tion of epinephrine than for the non-biphasic group
(p = 0.002). The median time from hospital arrival to
administration of epinephrine was also significantly
longer in the biphasic group than the non-biphasic pa-
tients (p = 0.001). Of interest, Smit et al. observed
that the time interval from onset to presentation was
three times longer in biphasic than the non-biphasic
patients.35 Our study confirmed the association be-
tween the time interval from onset to presentation at
hospital was longer in biphasic patients. We postulate
that the slowly progressive symptoms in the patients
might delay their recognition and hospital arrival.
The delayed time intervals could predispose them to
have biphasic reaction and receive delayed admini-
stration of epinerphrine. These findings support the
early administration of epinephrine to prevent late-
phase anaphylaxis.29 The delayed administration of
epinephrine, caused by delayed hospital arrival or de-
layed recognition for treatment, was associated with a
higher rate of complications and mortality.33 We rec-
ommend giving epinephrine as early as possible, to
prevent morbidity and mortality. Patients at risk or
with a previous history of anaphylaxis should be edu-
cated to use self-administered epinephrine. Training
the patient to use auto-injected epinephrine using the
correct method and at the correct time is beneficial
and will reduce mortality from anaphylaxis.36,37
Food-related anaphylaxis is common. Early admini-
stration of epinephrine is critical and significantly as-
sociated with lower morbidity from anaphylaxis. Phy-
sicians should be more aware of the emergence of
anaphylaxis, for prompt recognition and immediate
management.
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